Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Tonix Pharma (TNXP) Stock Price & Analysis

5,134 Followers

TNXP Stock Chart & Stats

$3.01-$0.23(-7.10%)
At close: 4:00 PM EST
$5$10Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$2.90 - $3.25
52-Week Range
$2.90 - $20.56
Previous Close
$3.24
Volume
N/A
Average Volume (3M)
1.16M
Market Cap
$58.49M
Enterprise Value
$18.07M
Total Cash (Recent Filing)
$162.79K
Total Debt (Recent Filing)
$1,253
Price to Earnings (P/E)
―
Beta
1.34
Next Earnings
Mar 15, 2027 (Est.)
EPS Estimate
-2.48
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Rapid Revenue Growth And High Gross Margin

Rapid revenue expansion and a high gross margin show that Tonix has established meaningful commercial traction, particularly as its product portfolio develops. If growth persists, the strong gross-profit profile could provide operating leverage and support reinvestment in the pipeline over the next several quarters.

TONMYA Commercial Momentum

TONMYA sales growth provides evidence of product adoption and gives Tonix an emerging commercial revenue base rather than relying solely on clinical milestones. Continued prescription expansion, supported by the larger sales force and payer access, could strengthen recurring revenue potential through 2027.

Low Financial Leverage

Very low leverage limits interest obligations and reduces the balance-sheet pressure associated with debt financing. This gives Tonix greater flexibility to direct available capital toward commercial execution and clinical programs, although the benefit depends on controlling losses and preserving liquidity.

Bears Say

Persistent Operating Losses

The scale of operating and net losses substantially outweighs current revenue growth, showing that Tonix has not yet demonstrated a sustainable earnings model. Continued losses can absorb the benefits of rising sales, delay self-funded development, and increase dependence on external capital.

Heavy And Worsening Cash Burn

Large negative operating and free cash flow indicate that commercial growth is not yet translating into internally funded operations. The worsening absolute burn can shorten financial flexibility, require additional financing, and constrain the pace at which Tonix advances its pipeline without dilution or other funding.

TONMYA Patent Litigation Risk

The generic challenge directly threatens the durability of TONMYA’s market protection, which is important because the product is the company’s main commercial growth engine. Litigation may delay generic approval, but an adverse outcome could increase competition and weaken future revenue and investment returns.

Tonix Pharma News

TNXP FAQ

What was Tonix Pharma’s price range in the past 12 months?
Tonix Pharma lowest stock price was $2.90 and its highest was $20.56 in the past 12 months.
What is Tonix Pharma’s market cap?
Tonix Pharma’s market cap is $58.49M.
When is Tonix Pharma’s upcoming earnings report date?
Tonix Pharma’s next earnings report is estimated for Mar 15, 2027 (not yet confirmed), which is in 120 days.
How were Tonix Pharma’s earnings last quarter?
Tonix Pharma released its earnings results on Nov 09, 2026. The company reported -$2.89 earnings per share for the quarter, missing the consensus estimate of -$2.389 by -$0.501.
Is Tonix Pharma overvalued?
According to Wall Street analysts Tonix Pharma’s price is currently Undervalued.
Does Tonix Pharma pay dividends?
Tonix Pharma does not currently pay dividends.
What is Tonix Pharma’s EPS estimate?
Tonix Pharma’s EPS estimate is -2.48.
How many shares outstanding does Tonix Pharma have?
Tonix Pharma has 19,431,517 shares outstanding.
What happened to Tonix Pharma’s price movement after its last earnings report?
Tonix Pharma reported an EPS of -$2.89 in its last earnings report, missing expectations of -$2.389. Following the earnings report the stock price went down -5.274%.
Which hedge fund is a major shareholder of Tonix Pharma?
Hedge funds hold Tonix Pharma shares: the largest hedge-fund position in Tonix Pharma is 72,326,590 shares, and hedge funds increased their holdings by 429.9K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology